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The common virus integration site (VIS) Evi11 was recently identified within the gene encoding the hema-
topoietic G-protein-coupled peripheral cannabinoid receptor Cnr2 (also referred to as Cb2). Here we show that
Cnr2 is a frequent target (12%) for insertion of Cas-Br-M murine leukemia virus (MuLV) in primary tumors
in NIH/Swiss mice. Multiple provirus insertions in Evi11 were cloned and shown to be located within the 3*
untranslated region of the candidate proto-oncogene Cnr2. These results suggest that proviral insertion in the
Cnr2 gene is an important step in Cas-Br-M MuLV-induced leukemogenesis in NIH/Swiss mice. To isolate
Evi11/Cnr2 collaborating proto-oncogenes, we searched for novel common VISs in the Cas-Br-M MuLV-
induced primary tumors and identified a novel frequent common VIS, Evi12 (14%). Interestingly, 54% of the
Evi11/Cnr2-rearranged primary tumors contained insertions in Evi12 as well, which suggests cooperative
action of the target genes in these two common VISs in leukemogenesis. By interspecific backcross analysis it
was shown that Evi12 resides on mouse chromosome 10 in a region that shares homology with human
chromosomes 12q and 19p. Sequence analysis demonstrated that Evi12 is located upstream of the gene
encoding the molecular chaperone Tra1/Grp94, which was previously mapped to mouse chromosome 10 and
human chromosome 12q22–24. Thus, Tra1/Grp94 is a candidate target gene for retroviral activation or
inactivation in Evi12. However, Northern and Western blot analyses did not provide evidence that proviral
insertion had altered the expression of Tra1/Grp94. Additional studies are required to determine whether
Tra1/Grp94 or another candidate proto-oncogene in Evi12 is involved in leukemogenesis.
During leukemogenesis hematopoietic progenitor cells ac-
quire growth advantages, expand, and accumulate in bone
marrow, blood, and other hematopoietic tissues. In this pro-
cess the expression patterns of multiple critical genes involved
in hematopoietic cell proliferation and differentiation change.
Human leukemias frequently contain chromosomal transloca-
tions (42) and, as a consequence, proto-oncogenes located
near these translocations become aberrantly expressed, result-
ing in the clonal outgrowth of leukemic cells. Retroviral inser-
tional mutagenesis represents an elegant way to study genes
involved in hematopoietic tumor formation in mice (21, 55).
Retroviral insertion results in activation of proto-oncogenes (2,
22, 35, 36, 40) or inactivation of tumor suppressor genes (7).
Multiple human proto-oncogenes and tumor suppressors, e.g.,
EVI1 (34), NF1 (47), and HOXA9 (39) have been shown to be
involved in murine hematopoietic transformation (7, 35, 40) as
well, which shows that retroviral insertional mutagenesis in
mice clearly shares common features with tumorigenesis in
humans. It has generally been accepted that tumor initiation
and progression is a multistep process (1, 18, 53). The latency
period of several months between retroviral infection and
manifestation of the disease suggests that multiple integrations
representing mutations in various critical genes may be neces-
sary for complete transformation (21). The cooperation of
tumor-inducing genes in leukemia progression has convinc-
ingly been demonstrated in proto-oncogene-bearing transgenic
mice, which develop tumors more rapidly after retroviral in-
fection than do virus-infected control littermates (1, 5). Thus,
the collaboration of various mutated genes can be explored in
mouse models by using retroviral insertional mutagenesis. The
coexistence of two common virus integration sites (VISs) in
multiple tumors may provide an indication for the cooperation
of the target genes in malignant transformation (11, 21).
Recently, we identified a novel common VIS, Evi11, which is
located on mouse chromosome 4 in a region that shares ho-
mology with human chromosome 1p36 (51). The common VIS
Evi11 was initially identified in two retrovirally induced my-
eloid cell lines, NFS107 and NFS78. Subsequently, retroviral
insertions in Evi11 were also demonstrated in multiple primary
tumors (51). The cell lines as well as the primary tumors
originated from NIH/Swiss mice after inoculation with Cas-
Br-M murine leukemia virus (MuLV) (17, 51). The candidate
proto-oncogene in this locus is Cnr2, the gene encoding the
peripheral cannabinoid receptor (51). We and others have
shown that murine Cnr2 is specifically expressed in spleen,
thymus, blood cells, and hematopoietic cell lines (14, 37, 50).
An endogenous ligand for Cnr2, anandamide, enhances hema-
topoietic cell proliferation induced by various growth factors,
such as interleukin-3 (IL-3), erythropoietin, and granulocyte
and granulocyte-macrophage colony-stimulatory factors, in se-
rum-free medium (50). Together, these results suggest a role
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for aberrantly expressed Cnr2 receptors in leukemia develop-
ment.
In this study we investigated the exact location and the
frequency of retroviral insertions in Evi11/Cnr2 in a new panel
of 91 Cas-Br-M MuLV-induced primary tumors in NIH/Swiss
mice and 20 previously established cell lines (17, 19). Retrovi-
ral insertion in Evi11 occurred frequently, i.e., in 13 of 111
cases studied. These proviral integrations in Evi11 were mainly
located in the 39 untranslated region (UTR) of Cnr2. To search
for new common VISs and to isolate oncogenes cooperating
with Evi11/Cnr2, new provirus flanking cDNA fragments were
isolated from the Evi11/Cnr2-rearranged myeloid cell line
NFS107. We identified a novel frequent common VIS, Evi12,
which was found in 16 of our panel of 111 primary tumors and
cell lines. Proviruses in Evi12 inserted upstream of the gene
encoding the molecular chaperone Tra1/Grp94. Interestingly,
in 54% of the Evi11/Cnr2 rearranged tumors insertions were
also observed in Evi12, suggesting that the target proto-onco-
genes in Evi11/Cnr2 and Evi12 collaborate in leukemic trans-
formation.
MATERIALS AND METHODS
Cell lines. The myeloid cell line NFS107 was established in vitro from Cas-
Br-M MuLV-initiated primary tumors (17). The NFS (17) and DA (19) cell lines
were cultured in RPMI 1640 medium supplemented with penicillin (100 IU/ml),
streptomycin (100 ng/ml), 10% fetal calf serum, and murine IL-3 (1 mg/ml).
Primary tumors. Newborn NIH/Swiss mice were injected subcutaneously with
cell culture supernatant of Cas-Br-M MuLV producing NIH 3T3 cells (obtained
from H. Morse III and J. W. Hartley). Between 150 and 220 days after injection
the mice developed leukemias. Ninety-one leukemic mice were sacrificed when
moribund. Forty-seven leukemic mice had 5- to 10-fold-enlarged spleens, and 17
mice had slightly enlarged spleens (up to 2-fold). Lymph nodes and thymus were
isolated when they were enlarged. Cells from spleen, thymus, or lymph nodes
from 91 Cas-Br-M MuLV-infected mice (CSL [Cas-Br-M MuLV Swiss leukemia])
were cryopreserved in liquid nitrogen. From these cells, high-molecular-weight
DNA was isolated (46) for Southern blot analysis. To analyze the morphology
of the primary tumor cells, cells were examined after May-Gru¨nwald-Giemsa
staining.
PCRs. To determine the exact locations and orientations of Cas-Br-M provirus
in the Evi11 and Evi12 loci, PCR was carried out on 1 mg of genomic DNA from
the primary tumors with VIS-specific primers in combination with Cas-Br-M
MuLV long-terminal-repeat (LTR)-specific primers (Fig. 1A [Evi11] and 4A
[Evi12]). Insertions in Evi11 were amplified with primer CBR16 (59-GTATTTC
AACATCAACTTGG-39) and primer pLTR-A (59-CCGAAACTGCTTACCA
C-39) (cycling conditions were 1 min at 94°C, 1 min at 48°C, and 3 min at 72°C
[30 cycles]), followed by nested PCRs with CBR22 (59-CCTCTCATTGCTCTA
ACATG-39) and pLTR-B (59-CTGTTTGGCCCAACTTCAGCTG-39) (cycling
conditions were 1 min at 94°C, 1 min at 58°C, and 3 min at 72°C [30 cycles]). To
determine virus integrations in Evi12, PCR was carried out with primer p503-1
(59-GTGTGAAAACCCTAATTCCGG-39) and pLTR1 (59-GGGTCTCCTCA
GAGTGATTG-39) (cycling conditions were 1 min at 94°C, 1 min at 57°C, and 3
min at 72°C [30 cycles]), followed by PCR with p503-1 and pLTR2 (59-TAAGT
CGACTACCCGCCTCG-39) (cycling conditions were 1 min at 94°C, 1 min at
48°C, and 3 min at 72°C [30 cycles]). A reverse transcription-PCR (RT-PCR)
strategy was carried out to isolate cDNA fragments from NFS107 flanking VISs
as described previously (52). Poly(A)1 RNA was purified from NFS107 by
affinity chromatography with oligo(dT) cellulose columns (Pharmacia). Reverse
transcriptase reactions were performed for 1.5 h at 37°C with 3 mg of poly(A)1
RNA in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 1 mM dithio-
threitol, 0.5 mM deoxynucleoside triphosphates (dNTPs), 1 U of RNAguard
(Pharmacia), and 100 U of SuperScript RT (Gibco, Breda, The Netherlands).
For first-strand synthesis 40 mM oligo(dT) adapter [59-GTCGCGAATTCGTC-
GACGCG(dT)15-39] was used. Subsequently, PCR was carried out by using the
adapter primer (59-GTCGCGAATTCGTCGACGCG-39) in combination with
the LTR-specific primer pLTR1 (59-GGGTCTCCTCAGAGTGATTG-39) to
isolate the cDNA fragments adjacent to the VISs. The PCR reaction mixture
contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 150 mM
dNTPs, and 2.5 U of Taq polymerase (Pharmacia, Uppsala, Sweden). Reactions
started with 10 min at 94°C and ended with 10 min at 72°C. Products were cloned
into pBluescript II SK(1) (EcoRV) (Statagene, Westburg, Leusden, The Neth-
erlands) and sequenced.
Sequence analysis. Nucleotide sequencing was performed on the ABI 310
sequencer (Perkin-Elmer, Nieuwerkerk, The Netherlands). Fragments were
cloned into pBluescript II SK(1) and sequenced with T3, T7, or sequence-
specific primers. Deduced sequences were analyzed by using the BLAST network
service of the National Center for Biotechnology Information (NCBI).
Southern and Northern blot analysis. Southern and Northern blot analysis
were performed as described previously (51).
Interspecific backcross mapping. Interspecific backcross progeny were gener-
ated by mating (C57BL/6J 3 Mus spretus)F1 females and C57BL/6J males as
described previously (10). A total of 205 N2 backcross mice were used to map the
Evi12 locus (see Results for details). DNA isolation, restriction enzyme diges-
tion, agarose gel electrophoresis, Southern blot transfer, and hybridization were
performed essentially as described earlier (20). All blots were prepared with
Hybond-N1 nylon membrane (Amersham). The 503 probe, a 233-bp cDNA
fragment flanking a VIS in NFS107, was labelled with [a-32P]dCTP by using a
random prime labelling kit (Stratagene); washing was done to a final stringency
of 1.03 SSCP (0.12 M NaCl plus 15 mM Na3C6H5O7 and 20 mM NaPO4)–0.1%
sodium dodecyl sulfate at 65°C. A 5.5-kb fragment was detected in
HindIII-digested C57BL/6J DNA, and a fragment of 4.3 kb was detected in
HindIII-digested M. spretus DNA. The presence or absence of the 4.3-kb HindIII
M. spretus-specific fragment was monitored in backcross mice.
A description of the probes and the restriction fragment length polymorphisms
(RFLPs) for the loci linked to the Evi12 locus, including Gna15, Pah and Tmpo,
been reported previously (3, 54). Recombination distances were calculated by
using Map Manager, version 2.6.5. The gene order was determined by minimiz-
ing the number of recombination events required to explain the allele distribu-
tion patterns.
Western blot analysis. NFS cells were washed with ice-cold phosphate-buff-
ered saline with 10 mM Na3VO4. Subsequently, cells were spun down and lysed
by incubation for 10 min at 4°C in lysis buffer (50 mM Tris-HCl, pH 8.0; 100 mM
NaCl; 1% Triton X-100; 0.1 mM Na3VO4; 1% Pefabloc SC; 50 mg of aprotinin,
50 mg of leupeptin, 50 mg of bacitracin, and 50 mg of iodoacetamide per ml; and
1 mM dithiothreitol). Insoluble material was removed by centrifugation for 30
min at 10,000 3 g at 4°C. After sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, proteins were electroblotted onto nitrocellulose (0.2 mm; Schlei-
cher & Schuell, Dassel, Germany). Filters were blocked by incubation in 0.3%
Tween 20 in Tris-buffered saline (TBS; 10 mM Tris-HCl, pH 7.4; 150 mM NaCl)
for 1 h at 37°C, washed in TBST (0.05% Tween 20 in TBS), and incubated with
antibodies diluted in TBST. The Grp94 antibody used for Western blotting was
goat polyclonal anti-Grp94 (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.).
After being washed with TBST, immune complexes were detected with horse-
radish peroxidase-conjugated anti-goat immunoglobulin Gspecific antiserum
(Santa Cruz Biotechnology), followed by an enhanced chemiluminescence reac-
tion (DuPont, Boston, Mass.).
Nucleotide sequence accession number. The accession number for the 1.7-kb
fragment containing the Cas-Br-M MuLV insertion sites is AF091114.
RESULTS
Frequent retroviral insertions in the Cnr2 gene in Evi11.
Recently, we demonstrated that retroviral insertions in the
Evi11 locus in two Cas-Br-M MuLV-induced cell lines, NFS78
and NFS107, and in five Cas-Br-M MuLV-induced primary
tumors occurred in the Cnr2 gene (51). To determine the
frequency of retroviral insertions in Evi11, we screened DNA
from a panel of 111 leukemias, i.e., 91 Cas-Br-M MuLV-in-
duced tumors and 20 cell lines (17, 19) by Southern blot anal-
ysis with a probe complementary to the protein-coding region
of Cnr2 (probe C, Fig. 1A) (reference 51 and data not shown).
Rearrangements in Evi11/Cnr2 were found in 13 of 111 cases
(12%; Table 1). Based on the restriction enzyme map of Cas-
Br-M MuLV (accession number X57540) and the restriction
sites within the Evi11/Cnr2 locus (51), the orientations of the
retroviruses were determined (Fig. 1A). In all primary tumors
provirus integrations occurred in the same orientation, i.e., in
the direction of transcription of the Cnr2 gene. After PCR
(Fig. 1A) with the LTR-specific primers pLTR-A and pLTR-B
in combination with the Cnr2-specific primers CBR16 and
CBR22, respectively, the exact sites of proviral insertion in a
number of primary tumors were determined (Fig. 1B). As
shown in Fig. 1B, all proviruses, except CSL75, were located in
the 39 UTR of the Cnr2 gene. Based on Southern blot analysis,
it was concluded that as a result of recombination the genomic
structure of the Evi11 locus in CSL63 was altered (data not
shown). How retroviral insertion affects expression of Cnr2
receptors in the Cnr2-mutated leukemias is the subject of cur-
rent investigations. In this study we focus on the identification
of novel common VISs representing transforming genes coop-
erating with Cnr2 in leukemogenesis.
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Identification of a novel common virus integration site,
Evi12. To isolate Evi11/Cnr2 cooperating transforming genes,
we applied a novel RT-PCR technique (52) on RNA from
NFS107, a retrovirally induced myeloid tumor cell line with a
provirus insertion in Evi11/Cnr2 (51). Multiple novel cDNA
fragments flanking provirus were isolated from NFS107 (data
not shown). A cDNA fragment of 233 bp, designated 503, was
cloned into pBluescript SK(1) and sequenced (see Fig. 4B).
No homologous sequences were found by searching the data-
base of the NCBI. RT-PCR analysis with primer set 503-2 (see
Fig. 4B) and pLTR1 demonstrated high mRNA expression of
cDNA fragment 503 in NFS107 compared to control cell lines.
It is at present uncertain whether cDNA fragment 503 repre-
sents a transcript of a cellular gene (52), since no mRNA was
detected in RNA from various murine tissues by using North-
ern blot analysis or RNase protection analysis (data not
shown). However, Southern blot analysis with 503 on high-
molecular-weight DNA from all 91 Cas-Br-M MuLV-induced
primary tumors demonstrated rearranged alleles in a number
of independent tumors, e.g., CSL17, CSL27, CSL29, CSL85,
CSL89, CSL93, and CSL97 (Fig. 2). From Southern blot anal-
yses of the primary tumors digested with multiple enzymes and
the restriction enzyme map of Cas-Br-M MuLV (accession
number X57540), it was concluded that the DNA rearrange-
ments were indeed the result of proviral integration (data not
shown). To date, we have identified rearrangements in this
locus in 15 of 91 primary tumors, and we have designated this
ecotropic virus integration site 12 or Evi12. From the 20 cell
lines studied so far, an Evi12 rearrangement was shown in one
cell line, i.e., NFS107.
Insertion of mink cell focus-forming (MCF) viruses in
Evi11/Cnr2 and Evi12. The primary tumors were isolated from
the outbred NIH/Swiss mice that were infected with ecotropic
Cas-Br-M MuLV (15, 25). Inoculation of NFS/N and NIH/
Swiss mice with Cas-Br-M MuLV results in the production of
both ecotropic and MCF recombinant MuLVs (16, 25). Most
of the MCF MuLVs are identified by a unique EcoRI site
within the env gene in the proviral genome (44). Interestingly,
based on the size of the rearranged alleles after EcoRI diges-
tion in Evi11/Cnr2-rearranged tumors (ca. 1.6 kb; Fig. 1C), an
EcoRI site must be located just downstream of the 59 LTR.
The size of the rearranged alleles after EcoRI digestion in
Evi12-rearranged tumors (ca. 2.0 kb; Fig. 2) is indicative for the
MCF virus unique EcoRI site at 6.9 kb of the proviral genome
(44). Southern blot analysis demonstrated that in the Cas-
Br-M MuLV-induced primary tumors, all proviruses in either
Evi11/Cnr2 or Evi12 are of the MCF type (Table 1).
Evi12 is located on the central region of mouse chromosome
10. The mouse chromosomal location of Evi12 was determined
by interspecific backcross analysis by using progeny derived
FIG. 1. Isolation of Cas-Br-M MuLV proviral insertions in Evi11/Cnr2. (A) Schematic representation of the Cnr2 gene in the Evi11 locus and the orientation and
site of integration of proviral DNA within the 39 UTR of Cnr2 in the primary tumors (CSLs). The locations of the primers used for PCR amplification on genomic DNA,
i.e., primers set CBR16 and pLTR-A followed by CBR22 and pLTR-B are indicated by small arrows. Probe C used for Southern blot analysis of the primary tumors
(data not shown and reference 51) is indicated. The protein-coding region of the Cnr2 gene is indicated by the black box. (B) Exact locations of the proviral integrations
in various independent Cas-Br-M MuLV-induced primary tumors in the 39 UTR of the Cnr2 gene. An arrow with a CSL number indicates the insertion site in this
particular tumor. Probe D was used for Southern blot analysis (Fig. 1C). The protein-coding region of the Cnr2 gene is indicated by the black box. (C) Southern blot
analysis of high-molecular-weight DNA of Cas-Br-M MuLV-induced primary tumors digested with EcoRI to detect MCF viruses. Hybridizations were performed with
probe D (HindIII/NcoI fragment [at bp 2,474 and 2,974 of the Cnr2 cDNA, respectively) (Fig. 1B) (51). Since this probe contains an EcoRI site, two bands representing
a normal allele appear indicated by arrows. Rearranged fragments of approximately 1.6 kb were detected in CSL13, CSL16, CSL27, and CSL74 but not in the control
tumors CSL102 and CSL12 without rearrangements in Evi11/Cnr2 (S, spleen; T, thymus; L, lymph nodes). The rearranged fragments represent the leukemic cell
population containing provirus in Evi11/Cnr2.
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from matings of ([C57BL/6J 3 Mus spretus]F1 females 3
C57BL/6J) mice. This interspecific backcross mapping panel
has been typed for over 2,500 loci that are well distributed
among all autosomes, as well as the X chromosome (10).
C57BL/6J and M. spretus DNAs were digested with several
enzymes and analyzed by Southern blot hybridization for in-
formative RFLPs by using the 233-bp mouse 503 cDNA probe.
The 4.3-kb HindIII M. spretus RFLP (see Materials and Meth-
ods) was used to monitor the segregation of the Evi12 locus in
backcross mice. The mapping results indicated that Evi12 is
located in the central region of mouse chromosome 10 linked
to Gna15, Pah, and Tmpo. Although 126 mice were analyzed
for every marker and are shown in the segregation analysis
(Fig. 3), up to 177 mice were typed for some pairs of markers.
Each locus was analyzed in pairwise combinations for recom-
bination frequencies with the additional data. The ratios of the
total number of mice exhibiting recombinant chromosomes to
the total number of mice analyzed for each pair of loci and the
most likely gene order are as follows: centromere - Gna15 -
7/139 - Evi12 - 1/137 - Pah - 5/177 - Tmpo. The recombination
frequencies (expressed as genetic distances in centiMorgans
[cM] 6 the standard error) are as follows: - Gna15 - 5.0 6 1.9
- Evi12 - 0.7 6 0.7 - Pah - 2.8 6 1.3 - Tmpo. We have compared
our interspecific backcross map of chromosome 10 with a com-
posite mouse linkage map that reports the map location of
many uncloned mouse mutations (provided from The Mouse
Genome Database, a computerized database maintained at
The Jackson Laboratory, Bar Harbor, Maine). Evi12 mapped
in a region of the composite map that lacks mouse mutations
with a phenotype that might be expected for an alteration in
this locus (data not shown). The central region of mouse chro-
mosome 10 shares regions of homology with human chromo-
somes 19p and 12q (summarized in Fig. 3), suggesting that the
human homolog of Evi12 will map to 19p or 12q.
Evi12 is located near the promoter region of the Tra1/Grp94
gene. Following a PCR approach (Fig. 4A), we have cloned the
MuLV integration sites in Evi12 from 13 primary tumors (Fig.
4B). These Evi12 proviral insertions were located within a
region of approximately 1.7 kb and had been inserted opposite
to the proviral integration in NFS107 (Fig. 4B and 5). The
nucleotide sequence of the 1.7-kb PCR fragment from CSL16
was compared with sequences in the NCBI database and dem-
onstrated high homology with the promoter region of the Sus
scrofa Ppk98 gene (X90848) (Fig. 4B) (12, 13). The murine
homolog of porcine Ppk98 is Tra1/Grp94 (also referred to as
Erp99, endoplasmin, and Gp96 in other studies). The gene
encoding Tra1/Grp94 is located on mouse chromosome 10 (49)
in a region that shares homology with human chromosome 12q
(28, 45). This suggested that the retroviral integrations in Evi12
were located upstream of the murine Tra1/Grp94 gene. The
233-bp fragment 503 was, subsequently, used to screen an
embryonic stem cell (E14) mouse genomic library to isolate
genomic DNA fragments representing the Evi12 locus. One
phage clone (l503) was isolated and used to generate a restric-
tion enzyme map (Fig. 5). This map showed identity with the 59
region of the mouse Tra1/Grp94 gene (48), which confirmed
that Evi12 is indeed located upstream of the gene encoding the
TABLE 1. Evi11 and Evi12 insertions in Cas-Br-M MuLV-induced
CSL primary tumors in NIH/Swiss micea
Tumor





CSL11 Spleen ND 137 M
CSL12 Spleen and thymus ND 148 PCR M
CSL13 Spleen ND † 166 M M
CSL14 Thymus and spleen ND 167 M M
CSL15 Spleen ND † 170 M
CSL16 Lymph node Lymphoid 196 M M
CSL17 Thymus Lymphoid 175 M
CSL23 Spleen ND 203 PCR
CSL27 Thymus and spleen Immature blasts 191 M M
CSL29 Spleen ND † 208 M
CSL35 Spleen Immature blasts 196 M
CSL60 Spleen Immature blasts 224 M
CSL63 Thymus Lymphoid 209 M [R]
CSL74 Spleen ND 216 M
CSL75 Spleen ND 216 M
CSL85 Spleen Immature blasts 210 M
CSL89 Lymph node and
spleen
Immature blasts 229 M
CSL93 Spleen ND † 229 M
CSL97 Spleen ND † 253 M M
CSL105 Spleen Immature blasts 294 M
NFS78 Cell line Myeloid E
NFS107 Cell line Myeloid M E
a Abbreviations (phenotypes were determined by morphology after May-
Gru¨nwald staining): M, MCF MuLV; E, ecotropic MuLV; [R], unable to deter-
mine exact MuLV insertion in the Cb2 gene because of recombination of the
Evi11/Cb2 locus; ND, not determined; PCR, rearrangement undetectable by
Southern blot analysis, proviral insertion determined by PCR (Fig. 1B). A dagger
indicates the mice were dead.
FIG. 2. Identification of common virus integration site Evi12. Southern blot
analysis of high-molecular-weight DNA of NFS107 and a number of Cas-Br-M
MuLV-induced primary tumors (CSL) digested with EcoRI or SstI. Filters were
hybridized with fragment 503 (Fig. 6). Rearrangements (2.0 kb) were detected in
CSL17, CSL27, CSL29, CSL85, CSL89, CSL93, and CSL97 but not in with the
control tumors CSL22, CSL91, and CSL96 (S, spleen; T, thymus; L, lymph
nodes). Arrows indicate the normal nonrearranged alleles.
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molecular chaperone, Tra1/Grp94 (Fig. 5). Moreover, se-
quence analysis demonstrated coding sequences of Tra1/Grp94
on a 1.6-kb EcoRI fragment isolated from l503 (Fig. 5). Al-
though Tra1/Grp94 is constitutively expressed in the endoplas-
mic reticulum (ER) of all eukaryotic cells (30), we investigated
whether expression of this gene was altered in the myeloid cell
line NFS107 and the primary tumors CSL11 and CSL17, which
contain provirus in Evi12. Northern blot analysis demonstrated
comparable levels of Tra1/Grp94 mRNA in NFS107 and in cell
lines without retroviral insertions in Evi12, i.e., DA3, NFS22,
NFS60, NFS61, and NFS70 (Fig. 6A). Likewise, no changes in
Tra1/Grp94 mRNA expression were observed in CSL11 and
CSL17 (Fig. 6A). Moreover, no fusion or readthrough mRNA
transcripts of retroviral sequences and Tra1/Grp94 were appar-
ent by Northern blot analysis. Western blot analysis showed
comparable Tra1/Grp94 protein levels in NFS107 and control
cell lines without Evi12 insertions, i.e., NFS22, NFS61, NFS70,
and NFS78 (Fig. 6B). Recent studies showed that expression of
Tra1/Grp94 and the ER molecular chaperone Grp78 is tightly
regulated by hematopoietic growth factors (6). Although we
were able to reproduce the results of Brewer and coworkers,
i.e., induction of Tra1/Grp94 mRNA expression by IL-3 in
growth-factor-deprived cell lines, no differences were observed
between NFS107 (Evi12 provirus insertion) and DA3 (no
Evi12 provirus insertion) (data not shown). Together, these
results indicated that Grp94 is located near the common VIS
Evi12 but that expression of the Tra1/Grp94 gene is not af-
fected as a result of proviral insertion in Evi12.
High coincidence of retroviral insertion in Evi11 and Evi12
in Cas-Br-M MuLV-induced primary tumors. The Evi12 flank-
FIG. 3. Evi12 maps in the central region of mouse chromosome 10. Evi12 was
placed on mouse chromosome 10 by interspecific backcross analysis. The segre-
gation patterns of Evi12 and flanking genes in 126 backcross animals that were
typed for all loci are shown at the top of the figure. For individual pairs of loci,
more than 126 animals were typed (see text). Each column represents the
chromosome identified in the backcross progeny that was inherited from the
(C57BL/6J 3 M. spretus)F1 parent. The shaded boxes represent the presence of
a C57BL/6J allele, and the white boxes represent the presence of a M. spretus
allele. The number of offspring inheriting each type of chromosome is listed at
the bottom of each column. A partial chromosome 10 linkage map showing the
location of Evi12 in relation to linked genes is shown at the bottom of the figure.
Recombination distances between loci in centiMorgans (cM) are shown to the
left of the chromosome, and the positions of loci in human chromosomes are
shown to the right. References for human map positions can be obtained from
the GDB (Genome Data Base), a computerized database of human linkage
information maintained by The William H. Welch Medical Library of The Johns
Hopkins University (Baltimore, Md.).
FIG. 4. Locations of proviral insertions in the Evi12 locus. (A) Representa-
tion of the proviral integration in Evi12 in the myeloid cell line NFS107. Frag-
ment 503 flanking provirus in NFS107 and the orientation and site of insertion
of the proviruses in the primary tumors (CSLs) are shown. VISs were amplified
with primer set p503-1 and pLTR1 followed by p503-1 and pLTR2. (B) DNA
sequence of the 1.7-kb region and the locations and orientations of the retroviral
integrations in Evi12 identified in the myeloid cell line NFS107 and the Cas-Br-M
MuLV-induced primary tumors (CSL). The first 233 bp represent fragment 503.
Both 503-specific primers, p503-1 and p503-2, are indicated by an arrow. cDNA
synthesis of fragment 503 was primed on the poly(A) stretch from 234 to 276 bp.
The region homologous to the promoter of the S. scrofa ppk98 gene (NCBI; E
value, 1.1026) is double underlined.
VOL. 73, 1999 COINCIDENCE OF Evi11/Cnr2 AND Evi12 3599
ing cDNA 503 was isolated from the IL-3-dependent myeloid
cell line NFS107 that also contains an insertion in Evi11/Cnr2.
In fact, 54% of the tumors, i.e., 7 of 13, bearing provirus within
Evi11/Cnr2 contained insertions in the novel common VIS
Evi12 as well (Table 1). The equal intensities of the rearrange-
ments in Evi11 or Evi12 in each tumor containing insertions in
both these loci shown by Southern blot analysis suggest a clonal
outgrowth of leukemic cells (data not shown). The high per-
centage of coincidence between Evi11 and Evi12 demonstrated
in this study provides evidence for cooperative transforming
activity between the target proto-oncogenes in Evi11 and
Evi12.
DISCUSSION
Tumor initiation and progression is a multistep process (1,
18, 53). Therefore, proviral insertion in Evi11/Cnr2 is probably
one of multiple genetic alterations required before a hemato-
poietic progenitor cell becomes fully malignant. Interestingly,
in outbred NIH/Swiss mice, Evi11/Cnr2 is a frequent target for
Cas-Br-M MuLV (12%). In an attempt to isolate Evi11/Cnr2
cooperating genes, novel provirus flanking cDNA fragments
were isolated (52). Clone 503 represented a novel common
VIS Evi12, which was found in 14% of the Cas-Br-M MuLV-
induced NIH/Swiss leukemias. More interestingly, 54% of the
tumors containing proviruses in the gene encoding the periph-
eral cannabinoid receptor Cnr2 also have insertions in Evi12.
Retroviral infection of Cnr2 transgenic mice (1, 5), with the
Cnr2 gene controlled by the Sca1 promoter (33), is currently
being performed to determine whether transgenic mice de-
velop leukemia earlier after Cas-Br-M MuLV injection than
control nontransgenic littermates. It is anticipated that retro-
viral infection of Cnr2 transgenics will add to our insight into
the cooperation between Evi11/Cnr2, the target gene in Evi12,
and other proto-oncogenes. Nevertheless, the frequent coinci-
dence of Evi11/Cnr2 and Evi12 in the Cas-Br-M MuLV-in-
duced primary tumors suggests that the target genes in these
two loci cooperate in leukemogenesis.
Evi12 is located upstream of the gene encoding the molec-
ular chaperone Tra1/Grp94. The glucose-regulated stress pro-
tein Tra1/Grp94 is involved in protein processing and stimu-
lates strong antitumor responses (41). Tra1/Grp94 is
ubiquitously expressed and the most abundant glycoprotein in
the ER of eukaryotic cells (30). Tra1/Grp94 and another ER
chaperone Grp78 are upregulated severalfold during differen-
tiation of the macrophage cell line M1 after IL-6 stimulation
(38) and Grp94/Grp78 also induces resistance to apoptosis (26,
27, 31). These examples suggest that changes in Tra1/Grp94
expression may affect normal differentiation or apoptosis of
hematopoietic cells. Furthermore, expression of TRA1/GRP94
is elevated in human breast cancer cells (25a) and increased
expression of Tra1/Grp94 in a model of rat colon adenocarci-
noma has been associated with greater tumorigenicity (32).
This would imply that provirus in Evi12 should increase the
expression of Tra1/Grp94. However, retroviral insertion in
Evi12 occurred outside the conserved regulatory elements that
are responsible for basal expression as well as the inducibility
of the Tra1/Grp94 promoter (8, 29), and we could not demon-
strate any significant changes in levels of Tra1/Grp94 expres-
sion in cells containing proviral insertions in Evi12. Moreover,
although it has recently been shown that Tra1/Grp94 is tightly
regulated by hematopoietic growth factors (6), no differences
in the regulation of Tra1/Grp94 expression after IL-3 starvation
and IL-3 stimulation were observed in NFS107 compared to
DA3 cells (data not shown). Thus, our results do not provide
evidence to support the hypothesis that Tra1/Grp94 represents
the proto-oncogene affected by proviral insertion in the my-
eloid cell line NFS107 or the Cas-Br-M MuLV-induced pri-
mary tumors.
The proviruses in the Cas-Br-M MuLV-induced primary
leukemias integrated in the opposite orientation compared to
the direction of transcription of Tra1/Grp94 (Fig. 6). This
might suggest that not Tra1/Grp94 but another gene down-
stream of the provirus insertions is the proviral target in Evi12.
The transcriptional activation of this potential target gene may
be by promoter insertion since proviruses integrated in a rel-
atively small region of 1.7 kb (21, 55). To identify other po-
tential proto-oncogenes in Evi12, an exon trapping system that
we recently developed (51) is currently being applied to several
bacterial artificial chromosome clones covering approximately
250 kb of the Evi12 locus.
Since leukemic spleen and thymus contain normal tissue as
well and the amount of normal tissue depends on the degree of
tumor progression, frequent low intensity of the rearranged
FIG. 5. Restriction enzyme map of the Evi12 locus. Restriction map of the
genomic phage l503 representing the Evi12 locus (Sl, SalI; S, SstI; BH, BamHI;
P, PstI; B, BglII; H, HindIII; X, XbaI; E, EcoRI). The proviral insertion region
of 1.7 kb is flanked by the virus integration sites in NFS107 and CSL16. Arrows
indicate the viral insertions in the other CSL tumors. The locations of the first
three exons of the Tra1/Grp94 gene are depicted as boxes, with the protein-
coding region in black. The 1.6-kb EcoRI fragment used for sequence analysis
and the cDNA fragment 503 flanking the Evi12 VIS in NFS107 are indicated
below the restriction map.
FIG. 6. Expression of Tra1/Grp94 mRNA in NFS cell lines and primary
tumors. (A) Northern blot analysis of MuLV-induced cell lines DA3, NFS22,
NFS60, NFS61, NFS70, and NFS107 (Evi12) and primary tumors CSL11 (Evi12)
and CSL17 (Evi12). Filters were hybridized with full-length cDNA of Tra1/Grp94
(30) cloned from NFS22. (B) Western blot analysis of MuLV-induced cell lines
NFS22, NFS61, NFS70, NFS78, and NFS107 (Evi12) with an anti-Grp94 anti-
body.
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Evi11 and Evi12 alleles in relation to the normal as well as
variation between the primary tumors was shown by Southern
blot analysis. Underrepresentation of the rearranged allele
may be caused by polymorphism. However, since most of the
proviral insertions have been cloned and sequenced and since
Southern blot analysis of all tumors has been carried out with
multiple restriction enzymes, the possibility of rearrangements
as a result of polymorphism in the outbred NIH/Swiss mice is
excluded.
In the cases of Evi11 and Evi12, there is a strong selective
advantage for integrations of MCF viruses. MCF viruses orig-
inate from recombination events between ecotropic MuLVs
with endogenous proviruses involving the retroviral env gene
and part of the LTR. Recombination results in the release of
leukemogenic MCF viruses with an altered host range and the
capability of superinfecting target cells. In a number of virus-
induced hematologic diseases, particularly T-cell lymphomas,
activation of the target proto-oncogene is regulated by inser-
tion of viruses of the MCF type (4, 9). Provirus in Evi11
contains a unique EcoRI site downstream of the 59 LTR and is
therefore distinct from the highly lymphomagenic NS-6(186)
MCF virus, which has been cloned from a thymic T-cell lym-
phoma in NFS mice inoculated with Cas-Br-M MuLV (9). In
Evi12 the proviral genomes contain an altered env region char-
acteristic for MCF viruses (44). Although, the exact role of
MCF viruses is still unclear, the invariable insertion of MCF
type proviruses and not Cas-Br-M MuLVs in Evi11/Cnr2 and
Evi12 suggests an important role for MCF viruses in the acti-
vation of the target proto-oncogenes.
Evi11/Cnr2 and Evi12 retroviral insertions have been found
in myeloid as well as in lymphocytic leukemias. Thus, there is
no apparent correlation between morphology of the leukemia
and proviral insertion in Evi11, Evi12, or both (Table 1). To
define the phenotypes of Evi11/Cnr2 and Evi12 rearranged as
well as nonrearranged leukemias more exactly, all primary
tumors are currently being analyzed by fluorescence-activated
cell sorter analysis with lymphoid- and myeloid-specific anti-
bodies. The fact that Evi11/Cnr2 and Evi12 were identified in
myeloid as well as in lymphoid lineages suggests that those
insertions are early transforming events of immature multipo-
tent progenitor cells. Other genetic defects may ultimately
determine whether immature myeloid or lymphoid cells accu-
mulate in the hematopoietic system.
Evi12 was mapped on mouse chromosome 10 by interspe-
cific backcross analysis, and this mapping result was confirmed
by the cytogenetic location of Tra1/Grp94 (28). No putative
proto-oncogenes have been identified in the mouse locus yet.
Evi12 is distinct from the known MuLV common integration
sites Mml1 (24) and Mis2 (43), which both map close to c-Myb
on mouse chromosome 10. TRA1/GRP94 was cytogenetically
mapped to human 12q24.2324.3 (49). Subsequently, human
TRA1/GRP94 was placed on a yeast artificial chromosome con-
tig representing 12q22–q23 (45). Thus, EVI12 is located on
human 12q22–24 as well. Although, no recurrent chromosomal
breakpoints in human acute myeloid leukemia (AML) have
been assigned to the human chromosomal region 12q22–24, an
individual AML patient with a translocation between 3q21 and
12q24 has been described (56). Interestingly, 12q22 and 12q24
breakpoints have been associated with chronic lymphocytic
leukemia (23) and B-cell non-Hodgkin lymphoma (57), respec-
tively. Thus, the chromosomal region 12q22–24 may be in-
volved in AML, chronic lymphocytic leukemia, or B-cell non-
Hodgkin lymphoma. It will be of interest to investigate
whether the Evi12 locus also represents a nonrandom chromo-
somal breakpoint region of human malignancies.
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